Company Overview
| Stock Name | 翰森製藥集團有限公司 |
|---|---|
| Stock Code | 03692 |
| Company Full Name | 翰森製藥集團有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事研發、生產及銷售藥品。 |
| Listing Date | 2019-06-14 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省連云港經濟技術開發區東晉路9號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | -- |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 14.26 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 34.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 550,293,400 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 19.5 |
|---|---|
| First Day Open | HK$ 16.3 |
| First Day Change | 36.75% |
| First Day Volume | 138363000.0 |
| First Day Turnover | 2452210000.0 |
Use of Proceeds
| Use of Proceeds | 1、所得款項凈額約45%或3,438百港元用于研發（包括我們現有及未來的國內及海 外藥物開發項目）、擴充我們的研發團隊及于研發技術的投資； 2、約25%或1,910百港元用于生產體系，建設新生產線，升級現有生產設施并提 高其自動化水平； 3、約20%或1,528百港元用于銷售及學術推廣，以配合新產品上市，尤其是四種 將自2019年至2020年上市的創新藥； 4、余款約10%或764百港元將用于撥付我們的營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
花旗环球金融亚洲有限公司 CE AAA137
Overall Coordinators (5)
摩根士丹利亚洲有限公司 CE AAD291
花旗环球金融亚洲有限公司 CE AAA137
UBS Securities Hong Kong Limited CE BIN466
高盛（亚洲）有限责任公司 CE ACC536
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (6)
摩根士丹利亚洲有限公司 CE AAD291
花旗环球金融亚洲有限公司 CE AAA137
UBS Securities Hong Kong Limited CE BIN466
高盛（亚洲）有限责任公司 CE ACC536
招商证券（香港）有限公司 CE AAI650
中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (7)
摩根士丹利亚洲有限公司 CE AAD291
花旗环球金融亚洲有限公司 CE AAA137
UBS Securities Hong Kong Limited CE BIN466
高盛（亚洲）有限责任公司 CE ACC536
招商证券（香港）有限公司 CE AAI650
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Ally Bridge LB Healthcare Master Fund Limited | 313,976,680 HKD | — | 3.99% | — | 6 months | 2019-12-14 |
| 2 | Boyu Capital Opportunities Master Fund | 470,950,760 HKD | — | 5.99% | — | 6 months | 2019-12-14 |
| 3 | Cormorant Asset Management, LP | 196,217,600 HKD | — | 2.50% | — | 6 months | 2019-12-14 |
| 4 | GIC Private Limited | 549,466,320 HKD | — | 6.99% | — | 6 months | 2019-12-14 |
| 5 | Hillhouse Funds | 228,758,920 HKD | — | 2.91% | — | 6 months | 2019-12-14 |
| 6 | Prime Capital Funds | 313,976,680 HKD | — | 3.99% | — | 6 months | 2019-12-14 |
| 7 | Vivo Funds | 156,974,080 HKD | — | 2.00% | — | 6 months | 2019-12-14 |
| 8 | Worldwide Healthcare Trust PLC | 313,976,680 HKD | — | 3.99% | — | 6 months | 2019-12-14 |
| 9 | 上海医药(香港)投资有限公司 | 156,974,080 HKD | — | 2.00% | — | 6 months | 2019-12-14 |
Directors & Management
| Chairman | 鐘慧娟 |
|---|---|
| Company Secretary | 鐘勝利,李亮賢 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 鐘慧娟(65.85%);岑均達(16.04%) |
|---|
